Welcome

Corporate Profile

News Releases

Mylan History

News Releases

Archives: Search / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004 / 2003 / 2002

2006 Archives

Dec 21, 2006

Mylan Laboratories Announces Closing of Public Offer to Acquire 20% of Matrix Laboratories Limited

Dec 19, 2006

Mylan Declares Quarterly Cash Dividend of $.06 Per Share

Dec 19, 2006

Mylan Announces Final FDA Approval for Finasteride Tablets USP, 5mg

Dec 6, 2006

Mylan Announces the Hiring of David F. Mulder to the Position of Senior Vice President, Corporate and Business Development

Nov 13, 2006

Mylan to Present at the 2006 Credit Suisse Healthcare Conference

Nov 10, 2006

Mylan Receives Final FDA Approval for Oxybutynin Chloride Extended-release Tablets

- Mylan Launches Immediately -

Nov 8, 2006

Mylan Announces Final FDA Approval for Doxycycline Tablets

Nov 1, 2006

Mylan Reports Second Quarter Fiscal 2007 Adjusted Diluted EPS of $0.37

Highest Quarterly and Six-Month GAAP Diluted EPS in Company's History

Oct 19, 2006

U.S. District Court Grants Mylan's Motion to Dismiss the '909 Patent in the Amlodipine Besylate Litigation

Ruling Addresses the Issue of Judicial Jurisdiction Based on Pediatric Exclusivity

Oct 19, 2006

Mylan Schedules Second Quarter Fiscal 2007 Financial Results Conference Call and Live Webcast

Sep 19, 2006

Mylan Declares Quarterly Cash Dividend of $.06 Per Share

Sep 12, 2006

Mylan Announces Final FDA Approval for Topiramate Tablets

Sep 7, 2006

U.S. Court of Appeals Rules in Favor of Mylan in Oxybutynin Patent Litigation

- Mylan Plans to Immediately Launch Upon Final FDA Approval -

Aug 30, 2006

Mylan Announces Tentative Approval for Fluoxetine Capsules, USP

Aug 28, 2006

Mylan Laboratories to Acquire Up to 71.5% Controlling Interest in Matrix Laboratories

- Transaction Expected to be Accretive to Mylan in FY '08 -

Aug 14, 2006

Mylan Announces Tentative Approval for Venlafaxine Hydrochloride Tablets

Aug 7, 2006

Mylan Reaffirms Fiscal 2007 Adjusted EPS Guidance of $1.35 - $1.55

- Company Comments on Today's Trading Activity -

Aug 7, 2006

Mylan No Longer Anticipates Additional Generic Transdermal Fentanyl Approvals During Fiscal 2007

- Company Updates Expectations for Fentanyl Transdermal System -

Jul 26, 2006

Mylan Increases Fiscal 2007 Adjusted Guidance to $1.35 to $1.55 per Diluted Share and Reports Record Diluted EPS of $0.35 for the First Quarter of Fiscal 2007

Jul 26, 2006

Mylan Announces Issuance of Patent Covering EMSAM®

Jul 25, 2006

Mylan Announces Final Approval for Additional Strengths of Estradiol Transdermal Systems

Jul 20, 2006

Mylan Calls for End to Abusive Practices That Delay Access to Affordable Pharmaceuticals

Mylan Testifies Before Congress on Heels of Introduction of New Authorized Generic Legislation

Jul 20, 2006

Mylan Announces Final Approval for Meloxicam Tablets

Jul 18, 2006

Mylan Chosen to Testify Before Congress Concerning Authorized Generics, Citizen Petitions, Declaratory Judgments and Issues Concerning the Delay of Generic Pharmaceutical Approvals

Jul 14, 2006

Mylan Schedules First Quarter Fiscal 2007 Financial Results Conference Call and Live Webcast

1-25 26-45

The news releases on this page are included for historical puposes only. The information contained in each press release speaks only as of the date thereof and assumes no duty to update such information beyond the dates thereof.

Email Page